文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

局灶挽救性高剂量率近距离放疗治疗局部复发前列腺癌的疗效与毒性

Efficacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent prostate cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-03-27

本研究回顾性分析了2015至2018年间43例接受单次19 Gy高剂量率近距离放疗的局部复发前列腺癌患者,中位随访26个月,中位生化无进展生存期为35个月,1、2、3年bPFS分别为95.2%、70.6%、41.8%,仅观察到1例晚期3级泌尿生殖毒性。

要点

  • 单次19 Gy局灶挽救性HDR近距离放疗后中位bPFS为35个月。
  • 3年bPFS降至41.8%,提示需长期随访评估疗效持久性。
  • 仅1例晚期3级泌尿生殖毒性,严重毒性风险低。

核心结论

  • 局灶挽救性HDR近距离放疗可能提供良好的生化控制且严重毒性风险低,但需临床试验进一步评估其角色。

研究设计与样本

  • 回顾性队列研究,从机构数据库连续纳入2015至2018年间接受单次19 Gy HDR近距离放疗的局部复发前列腺癌患者43例。
  • 中位随访26个月(范围1-60个月),采用单变量分析评估患者、疾病和治疗因素与bPFS的关系。

主要发现

  • 中位bPFS为35个月(95%CI 25.6-44.4)。
  • 挽救治疗后1、2、3年bPFS的Kaplan-Meier估计分别为95.2%、70.6%、41.8%。
  • 单变量Cox回归分析中仅nadir PSA与bPFS显著相关,但多数患者同时接受了雄激素剥夺治疗。
  • 仅观察到1例晚期3级泌尿生殖毒性。

临床怎么用

  • 对于原发性放疗或近距离放疗后孤立局部复发的前列腺癌患者,可考虑局灶挽救性HDR近距离放疗。
  • 治疗决策需结合nadir PSA及是否联合雄激素剥夺治疗进行个体化评估。
  • 应告知患者3年bPFS约41.8%且需长期随访监测生化进展。

局限性

  • 回顾性研究设计,样本量较小(43例)。
  • 中位随访仅26个月,不足以评估长期疗效与晚期毒性。
  • 多数患者同时接受雄激素剥夺治疗,可能混淆bPFS的归因。
  • 缺乏高质量证据支持该方法的常规应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Isolated local recurrence of prostate cancer following primary radiotherapy or brachytherapy may be treated with focal salvage high dose rate brachytherapy, although there remains an absence of high quality evidence to support this approach. METHODS: Men with prostate cancer treated consecutively between 2015 and 2018 using 19 Gy in a single fraction high dose rate brachytherapy (HDR) for locally recurrent prostate cancer were identified from an institutional database. Univariable analysis was performed to evaluate the relationship between patient, disease and treatment factors with biochemical progression free survival (bPFS). RESULTS: 43 patients were eligible for evaluation. Median follow up duration was 26 months (range 1-60). Median bPFS was 35 months (95% confidence interval 25.6-44.4). Kaplan-Meier estimates for bPFS at 1, 2 and 3 years post salvage were 95.2%, 70.6% and 41.8% respectively. On univariable Cox regression analysis, only nadir PSA was significantly associated with bPFS although the majority of patients were also treated with androgen deprivation therapy. Only one late grade 3 genitourinary toxicity was observed. CONCLUSION: Focal salvage HDR brachytherapy may provide good biochemical control with a low risk of severe toxicity. Further evaluation within clinical trials are needed to establish its role in the management of locally recurrent prostate cancer.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Slevin F, Hodgson S, Rodda SL, et al. Efficacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent prostate cancer. Clin Transl Radiat Oncol. 2020. PMID: 32368626. doi:10.1016/j.ctro.2020.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。